Effectiveness of Cimetidine as Adjuvant Therapy in the Treatment of Acute-Extrinsic Atopic Dermatitis: A Double-Blind Randomized Controlled Trial

Endi Novianto, Tjut N A Jacoeb, Wresti Indriatmi, Suhendro, Rianto Setiabudy, Rahajuningsih D Setiabudy, Murdani Abdullah, Iris Rengganis, Oki Suwarsa, Retno W Soebaryo, Endi Novianto, Tjut N A Jacoeb, Wresti Indriatmi, Suhendro, Rianto Setiabudy, Rahajuningsih D Setiabudy, Murdani Abdullah, Iris Rengganis, Oki Suwarsa, Retno W Soebaryo

Abstract

Introduction: Acute extrinsic atopic dermatitis (AD) requires long-term treatment. Cimetidine could be used as an adjuvant therapy for acute-extrinsic AD due to immunomodulatory effects. This study aims to assess the effectiveness of cimetidine as an adjuvant to standard treatment in acute extrinsic AD.

Methods: This is a double-blind randomized controlled trial involving 26 AD patients aged 12-60 years from 2017 to 2020. Effectiveness of cimetidine was assessed by comparing SCORing Atopic Dermatitis (SCORAD) and objective SCORAD changes in both groups at week 2, 4, 6, and 8. Serum levels of immunoglobulin E (IgE), interferon (IFN)-γ, interleukin (IL)-12, and IL-4 were also documented.

Results: Significant differences were observed in SCORAD changes at week 2, 4, 6, and 8 (p = 0.004; p = 0.001; p < 0.001; and p < 0.001 respectively), objective SCORAD changes at week 2, 4, 6, and 8 (p = 0.004, p = 0.001, p < 0.001, and p < 0.001 respectively), and IgE level changes at week 8 (p = 0.002) between the two groups. However, there were no significant changes in IFN-γ, IL-12, and IL-4 levels between the two groups.

Conclusion: Cimetidine is a safe and effective adjuvant therapy for acute-extrinsic AD.

Trial registration: NCT04018131.

Keywords: Atopic dermatitis; Cimetidine; Efficacy; IgE level; SCORAD.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Participant flow of the study
Fig. 2
Fig. 2
Evaluation of SCORAD50 at each follow-up visit. a = Fischer’s exact test; b = Chi-squared test; *statistically significant difference

References

    1. Abuabara K, Yu AM, Okhovat JP, Allen IE, Langan SM. The prevalence of atopic dermatitis beyond childhood: A systematic review and meta-analysis of longitudinal studies. Allergy. 2018;73(3):696–704. doi: 10.1111/all.13320.
    1. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi: 10.1016/j.jaad.2014.03.023.
    1. Kabashima K. New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci. 2013;70(1):3–11. doi: 10.1016/j.jdermsci.2013.02.001.
    1. Leung DY, Guttman-Yassky E. Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol. 2014;134(4):769–779. doi: 10.1016/j.jaci.2014.08.008.
    1. Kulthanan K, Boochangkool K, Tuchinda P, Chularojanamontri L. Clinical features of the extrinsic and intrinsic types of adult-onset atopic dermatitis. Asia Pac Allergy. 2011;1(2):80–86. doi: 10.5415/apallergy.2011.1.2.80.
    1. Koszorú K, Borza J, Gulácsi L, Sárdy M. Quality of life in patients with atopic dermatitis. Cutis. 2019;104(3):174–177.
    1. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327–349. doi: 10.1016/j.jaad.2014.03.030.
    1. De Benedetto A, Yoshida T, Fridy S, Park JE, Kuo IH, Beck LA. Histamine and skin barrier: are histamine antagonists useful for the prevention or treatment of atopic dermatitis? J Clin Med. 2015;4(4):741–755. doi: 10.3390/jcm4040741.
    1. Sinha S, Relhan V, Garg VK. Immunomodulators in warts: Unexplored or ineffective? Indian J Dermatol. 2015;60(2):118–129. doi: 10.4103/0019-5154.152502.
    1. Branco ACCC, Yoshikawa FSY, Pietrobon AJ, Sato MN. Role of histamine in modulating the immune response and inflammation. Mediators Inflamm. 2018;2018:9524075. doi: 10.1155/2018/9524075.
    1. O'Mahony L, Akdis M, Akdis CA. Regulation of the immune response and inflammation by histamine and histamine receptors. J Allergy Clin Immunol. 2011;128(6):1153–1162. doi: 10.1016/j.jaci.2011.06.051.
    1. Chopra R, Silverberg JI. Assessing the severity of atopic dermatitis in clinical trials and practice. Clin Dermatol. 2018;36(5):606–615. doi: 10.1016/j.clindermatol.2018.05.012.
    1. Schmitt J, Langan S, Deckert S, Svensson A, von Kobyletzki L, Thomas K, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013;132(6):1337–1347. doi: 10.1016/j.jaci.2013.07.008.
    1. Bożek A, Reich A. Assessment of intra- and inter-rater reliability of three methods for measuring atopic dermatitis severity: EASI, Objective SCORAD, and IGA. Dermatology (Basel, Switzerland) 2017;233(1):16–22. doi: 10.1159/000472711.
    1. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67(1):99–106. doi: 10.1111/j.1398-9995.2011.02719.x.
    1. Goh YY, Keshavarzi F, Chew YL. Prevalence of atopic dermatitis and pattern of drug therapy in Malaysian children. Dermatitis. 2018;29(3):151–161. doi: 10.1097/DER.0000000000000376.
    1. Roekevisch E, Spuls PI, Kuester D, Limpens J, Schmitt J. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic review. J Allergy Clin Immunol. 2014;133(2):429–438. doi: 10.1016/j.jaci.2013.07.049.
    1. Carlos D, Sa-Nunes A, de Paula L, Matias-Peres C, Jamur MC, Oliver C, et al. Histamine modulates mast cell degranulation through an indirect mechanism in a model IgE-mediated reaction. Eur J Immunol. 2006;36(6):1494–1503. doi: 10.1002/eji.200535464.
    1. Lin AA, Freeman AF, Nutman TB. IL-10 indirectly downregulates IL-4-induced IgE production by human B cells. Immunohorizons. 2018;2(11):398–406. doi: 10.4049/immunohorizons.1800076.
    1. Ahmed I, Nasreen S. Frequency of raised serum IgE level in childhood atopic dermatitis. JPMA J Pak Med Assoc. 2007;57(9):431–434.
    1. Zedan K, Rasheed Z, Farouk Y, Alzolibani AA, Bin Saif G, Ismail HA, et al. Immunoglobulin e, interleukin-18 and interleukin-12 in patients with atopic dermatitis: correlation with disease activity. J Clin Diagn Res JCDR. 2015;9(4):Wc01-5.
    1. Kasperkiewicz M, Mook SC, Knuth-Rehr D, Vorobyev A, Ludwig RJ, Zillikens D, et al. IgE-selective immunoadsorption for severe atopic dermatitis. Front Med. 2018;5:27. doi: 10.3389/fmed.2018.00027.
    1. Zink A, Gensbaur A, Zirbs M, Seifert F, Suarez IL, Mourantchanian V, et al. Targeting IgE in severe atopic dermatitis with a combination of immunoadsorption and omalizumab. Acta Derm Venereol. 2016;96(1):72–76. doi: 10.2340/00015555-2165.
    1. Jordakieva G, Kundi M, Lemell P, Zieglmayer R, Zieglmayer P, Jensen-Jarolim E, et al. Cetirizine inhibits gender-specific blood cell dynamics upon allergen contact in allergic rhinitis. Clin Immunol. 2020;215:108422. doi: 10.1016/j.clim.2020.108422.
    1. Kamei M, Otani Y, Hayashi H, Nakamura T, Yanai K, Furuta K, et al. Suppression of IFN-γ production in murine splenocytes by histamine receptor antagonists. Int J Mol Sci. 2018;19(12):4083. doi: 10.3390/ijms19124083.
    1. Zundler S, Neurath MF. Interleukin-12: functional activities and implications for disease. Cytokine Growth Factor Rev. 2015;26(5):559–568. doi: 10.1016/j.cytogfr.2015.07.003.
    1. Arae K, Oboki K, Ohno T, Hirata M, Nakae S, Taguchi H, et al. Cimetidine enhances antigen-specific IgE and Th2 cytokine production. Allergol Int. 2011;60(3):339–344. doi: 10.2332/allergolint.10-OA-0255.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅